Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program Eterna Therapeutics Announces $1 Million Stock Repurchase Program

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) and Factor Bioscience Limited (“Factor”) today announced an exclusive license...